Sanofi is to pay Ablynx up to €2.4 billion to develop drugs for immune-related inflammatory diseases based on the biotech’s nanobody technology. The Paris-headquartered pharma firm is ...

In case of larger nanobody drug formats, opsonization and subsequent recognition and uptake by the reticuloendothelial system (RES) may occur, leading to hepatic clearance of these therapeutic ...

To address this challenge, researchers at the University of Minnesota and the Midwest Antiviral Drug Discovery (AViDD) Center have developed the first nanobody-based inhibitors targeting the Ebola ...

Introduction: The development of nanobodies targeting Programmed Cell Death Protein-1 (PD-1) offers a promising approach in cancer immunotherapy. This study aims to design and characterize a ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Sometimes you may receive a combination of therapies, or something else entirely. Oncology (cancer) drugs include a range of therapies and medications, such as chemotherapy drugs, targeted ...

New nanobody approach shows early promise against ... for which there are two U.S. approved human antibody drugs - Ebanga from Ridgeback Biotherapeutics and Inmazeb from Regeneron Pharmaceuticals ...

These findings support the potential of nanobody technology in addressing viral diseases ... The demonstrated potential of Nanosota-EB1 and Nanosota-EB2 as therapeutic agents underscores the ...

The first nanobody-based drug, Caplacizumab, was approved in 2018, and ongoing clinical trials are exploring the therapeutic potential of other nanobodies, such as ozoralizumab, which targets ...